Evidence map›Paper›PMID 35630024›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort.

Irena Conic, Bojan Nedovic, Slavica Stojnev, Ilinka Todorovska, Aleksandra Dimitrijevic, Miljan Krstic, Ivana Djordjevic, Biljana Djordjevic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Irena ConicFaculty of Medicine, University of Nis, 18000 Nis, Serbia.
Bojan NedovicFaculty of Medicine, University of Nis, 18000 Nis, Serbia.ORCID 0000-0002-9507-7128
Slavica StojnevFaculty of Medicine, University of Nis, 18000 Nis, Serbia.ORCID 0000-0001-5058-9720
Ilinka TodorovskaOncology Clinic, Clinical Center Nis, 18000 Nis, Serbia.
Aleksandra DimitrijevicFaculty of Medicine, University of Nis, 18000 Nis, Serbia.
Miljan KrsticFaculty of Medicine, University of Nis, 18000 Nis, Serbia.ORCID 0000-0003-2634-3450
Ivana DjordjevicFaculty of Medicine, University of Nis, 18000 Nis, Serbia.
Biljana DjordjevicFaculty of Medicine, University of Nis, 18000 Nis, Serbia.
University of Nis · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsAntibodies, Monoclonal, HumanizedBevacizumabCarboplatinFemaleHumansPaclitaxelSerbiaAntibodies, Monoclonal, HumanizedBevacizumabCarboplatinPaclitaxelbevacizumabovarian canceroverall survivalprogression-free survival

Identifiers

PMID35630024
PMCPMC9144683
OpenAlexW4225016405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.